Drugs / Euphrasia
Euphrasia
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04122300 | May 2011 → Dec 2016 | conjunctival disorder, lacrimal duct obstruction | University of Bern | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02416128 | Apr 2015 → Mar 2016 | iritis | Larkin Community Hospital | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Euphrasia | “Infants were randomly assigned (1:1) to the Euphrasia arm (Euphrasia eye drops®, Weleda AG, Arlesheim) or the placebo arm (NaCl 0.9%).” PMID 32850558 ↗ Aug 2020 |
| Known as | Euphrasia eye drops | “Infants were randomly assigned (1:1) to the Euphrasia arm (Euphrasia eye drops®, Weleda AG, Arlesheim) or the placebo arm (NaCl 0.9%).” PMID 32850558 ↗ Aug 2020 |
| Known as | Euphrasia Officinalis Preparation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04122300 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “The investigators plan to use an herbal eye drop, Euphrasia, aka Eyebright, for post-operative inflammation” NCT02416128 ↗ |
| Route | Topical | “Euphrasia when used topically to treat inflammatory conditions of the eye” NCT02416128 ↗ |